New results from a Phase 3 clinical trial comparing Alecensa (alectinib), currently approved as second-line therapy, with Xalkori (crizotinib), currently approved for first-line therapy in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) found the alectinib-treated group to have a statistically significant improvement in their progressive free survival (PFS).
particular, survival rates in pediatric cancers improved the greatest over the past few decades. In 1975-1977, 5-year survival was 58%. In the 2006-2012 time period, the 5-year survival rate jumped to 84.5%.
7-year-old Jake Vella enters triathlons to keep his weight down. He has a rare disease called ROHHAD that saw he weight gain over 20 lbs in 6 months, despite eating only salads.
Cale has Fanconi anemia, an ultra-rare blood disorder. At last count (when he was 7 years old) he had endured over 100 hospital stays and 26 surgeries. He thinks Creighton Blue Jays should win the NCAA tournament this year.
The battle for which drug will dominate advanced ovarian cancer treatment just got interesting. And regardless over which drug dominates, the true winner will be the patients given the very impressive data that is emerging.
From 1999 to 2015, a total of 45,221 deaths caused from mesothelioma in people older than 25-years-old were recorded in the US.
Hair loss, skin rash, dry skin, nail problems, bloating, bruising, and many other side effects can greatly impact the cancer patient's appearance. That does not mean they can’t have options.
At Rare Disease in Washington DC, we talked with Brian Wood about the years of being unable to properly get a diagnosis of extra adrenal pheochromatocytoma.
Othon Iliopoulos, MD, of Massachusetts General Hospital describes Von Hippel-Lindau (VHL) Disease and the research his team is doing to better manage this rare condition.
TV and radio personality Alan Colmes died following a brief battle with lymphoma. Mr Colmes was 66 years old. It is uncertain what type of lymphoma he had.